Atlas Trials

Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib

Clinical trial NCT04079738 · TERMINATED

Trial details

NCT number
NCT04079738
Sponsor
H Scott Boswell
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
AMLAML, Adult
Start date
2019-09-20
Primary completion
2021-09-22
Enrollment
8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.